We serve Chemical Name:3,6-Dibromopyridazine CAS:17973-86-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3,6-Dibromopyridazine
CAS.NO:17973-86-3
Synonyms:Pyridazine,3,6-dibromo;3,6-Dibromo pyridazine;Pyridazine, 3,6-dibromo-;3,6-Dibromopyridazine;3,6-Dibromo-1,2-diazine;3,6-Dibromopyridazide;3,6-dibromo-pyridazine;3,6-Dibrompyridazin;MFCD00233947;3,6-Dibromopyradazine
Molecular Formula:C4H2Br2N2
Molecular Weight:237.880
HS Code:2933990090
Physical and Chemical Properties:
Melting point:116-117ºC
Boiling point:327.5±22.0 °C at 760 mmHg
Density:2.2±0.1 g/cm3
Index of Refraction:1.616
PSA:25.78000
Exact Mass:235.858459
LogP:1.35
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:
Contact us for information like Pyridazine,3,6-dibromo chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3,6-Dibromopyradazine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3,6-dibromo-pyridazine Use and application,3,6-dibromo-pyridazine technical grade,usp/ep/jp grade.
Related News: The European Medicines Agency on Friday rejected Kyowa Kirin’s Parkinson’s disease drug Nouryant (istradefylline), which the US FDA approved in 2019 under the brand name Nourianz. 1H-pyrazin-2-one, sodium salt manufacturers After recently opening one cell therapy plant and breaking ground on another in Massachusetts, Takeda is pivoting westward to beef up production in California. 1-chloro-4-diethoxyphosphorylbenzene suppliers Contract research organisation Charles River Laboratories International Inc. today announced plans for an €8M expansion of its testing capabilities at its Ballina, Co. Mayo site that will give an additional 1,500m2 of lab space and create up to 90 new skilled roles over the next three years. 3-Oxetanecarbonitrile vendor & factory Grégoire Boutonnet, Chief Operating Officer of NOVA, said: “I am thrilled to be joining the NOVA team at this exciting period of growth as we launch the Jinkō platform towards wider adoption in the clinical trial development space. ,McNamara joined GSK from Novartis in 2015 when the two companies combined their OTC portfolios into a joint venture managed by GSK. He became head of GSK consumer health in 2016, taking the baton from Walmsley as she moved up the command chain to CEO of the entire group. Novartis in 2018 backed out of the collab, and after taking full control of the venture, GSK formed a new JV with Pfizer in 2019.
